Ratings MEDICLIN AG

Equities

MED

DE0006595101

Market Closed - Xetra Other stock markets 16:36:09 03/05/2024 BST			5-day change	1st Jan Change
2.92 ^EUR	-1.35%		+3.55%	+6.57%

04-30	MEDICLIN Aktiengesellschaft Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03-27	MEDICLIN Aktiengesellschaft Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Strengths

The company appears to be poorly valued given its net asset value.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
The company does not generate enough profits, which is an alarming weak point.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Revenue estimates are regularly revised downwards for the current and coming years.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Healthcare Facilities & Services

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
MEDICLIN AG	+6.57%	149M	-	C
AIER EYE HOSPITAL GROUP CO., LTD.	-18.46%	16.57B		B+
BANGKOK DUSIT MEDICAL SERVICES	+4.50%	12.51B		B
IHH HEALTHCARE	+4.31%	11.69B		B+
ENCOMPASS HEALTH CORPORATION	+24.72%	8.38B		B
RAMSAY HEALTH CARE LIMITED	-2.64%	7.75B		A-
MOUWASAT MEDICAL SERVICES COMPANY	+20.04%	7.16B		D
THE ENSIGN GROUP, INC.	+4.17%	6.6B		B-
GLOBAL HEALTH LIMITED	+46.90%	4.54B		-
DALLAH HEALTHCARE COMPANY	-5.70%	4.22B		-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes